Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Kumar S, et al.
Lancet Haematology
June 2025
Authors and Affiliates
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender,
Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Pothacamury, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A Ross,
Edyta Dobkowska, Philippe Moreau
Mayo Clinic, Rochester, MN,
USA (Prof S K Kumar MD);
Peter MacCallum Cancer Centre
and Royal Melbourne Hospital,
Melbourne, VIC, Australia
(Prof S J Harrison PhD);
Sir Peter MacCallum
Department of Oncology,
University of Melbourne,
Parkville, VIC, Australia
(Prof S J Harrison);
IRCCS Azienda Ospedaliero-
Universitaria di Bologna,
Seragnoli Institute
of Hematology, Bologna
University School of Medicine,
Bologna, Italy
(Prof M Cavo MD); Hematology
Service Hospital La Fe, IIS La Fe,
and School of Medicine and
Dentistry, Catholic University
of Valencia, Valencia, Spain
(Prof J de la Rubia MD);
University College London
Hospitals
NHS Foundation Trust,
London, UK (R Popat FRCPath);
Duke University Medical
Center, Durham, NC, USA
(Prof C Gasparetto MD); Clinica
São Germano, São Paulo, Brazil
(Prof V Hungria MD); Asklepios
Tumorzentrum Hamburg,
AK Altona and AK St Georg,
Hamburg, Germany
(H Salwender MD); Japanese
Red Cross Medical Center,
Tokyo, Japan
(Prof K Suzuki MD); Seoul
National University, Seoul,
South Korea (Prof I Kim MD);
Genentech, Inc, South
San Francisco, CA, USA
(M Onishi MD, G Ku MD);
AbbVie, North Chicago, IL,
USA (R Pothacamury MD,
M Jalaluddin PhD, J Zeng PhD,
J A Ross PhD); AbbVie,
Schaffhausen, Switzerland
(E Dobkowska MD); University
Hospital Hôtel-Dieu, Nantes,
France (Prof P Moreau MD)